URL Pharma, Inc. announced the launch of the Colcrys (colchicine, USP) Patient Assistance Programme, an initiative that will allow patients with limited means to save on Colcrys prescriptions. This programme reflects URL Pharma's ongoing commitment to helping ensure that all patients who rely on the company's medications are able to access them, regardless of economic status. Colcrys is indicated for the prevention and treatment of gout flares and for the treatment of Familial Mediterranean Fever (FMF).
"URL Pharma believes that patients should not be forced to sacrifice in order to afford their medication, especially in these difficult economic times," said Richard H. Roberts, MD, PhD, President, CEO and chairman, URL Pharma. "The Colcrys Patient Assistance Program will help ensure that limited income is not a barrier to patients who need Colcrys."
The Colcrys Patient Assistance Program will allow eligible uninsured patients to secure a 90-day supply of Colcrys for a $15 co-payment. The program is administered through Rx Outreach, a service provided by Express Scripts Specialty Distribution Services (ESSDS).
URL Pharma, Inc., headquartered in Philadelphia, PA, is a leading specialty pharmaceutical company with fully integrated technology development, product development, manufacturing, and commercialization capabilities.